Pharma Nord has been chosen to provide vitamin D for a major UK population study

BBC report on the study

BBC News has made a report that explains the background for focusing on vitamin D in relation to the immune system.

Chosen because of the documentation

For a period of six months, the approximately 6,000 study participants will be given either vitamin D in two different strengths or serve as a control group. 

All participants will be tested at baseline and are eligible for inclusion provided their vitamin D blood status is below the recommended level. 
Half the participants – the control group – will be advised to follow the official guidelines that recommend taking a daily 10-microgram supplement of vitamin D. These participants will not be monitored for compliance. 

The remaining participants will be divided in two groups with one group taking capsules with 20 micrograms of vitamin D daily for six months while the other half will be taking capsules with 80 micrograms of vitamin D. When the study is terminated, vitamin D levels will be measured again in the two supplemented groups.

The British study has received funding from Fischer Family Trust, a charity organization specialised in supporting medical research and education. It is also supported by Barts Charity and the Aim Foundation.  
The scientists have chosen a supplement with vitamin D from a danish company because previously published studies show that this brand is easily absorbed in the blood.

Norwegian studies showed good absorption

One study, which was conducted by researchers from the University of Oslo, was about muscle strength. The second, which was also carried out by Norwegian researchers, looked at the impact of vitamin D on school children's well-being.

In both studies, measurements showed that Pharma Nord's preparation caused the blood's content of vitamin D to increase significantly, which is a sign that it has good absorption.

Quality is crucial to the outcome

For more than 30 years, Pharma Nord has been a frontrunner and has put a particularly large amount of work into producing preparations with good bioavailability so that they are precisely suitable for scientific research. It is crucial for the outcome of a study that the active substance is absorbed into the blood and tissues. Over time, Pharma Nord has supplied preparations for several hundred clinical trials.
Two of the most significant studies are Q-Symbio (Bio-Qinon Q10) and KiSel-10 (Bio-Qinon Q10 and SelenoPrecise).

Both preparations are known within international research circles because they have documentation for good absorption. The studies have been published in some of the world's leading medical journals and have helped to increase the argument for using nutrients preventively.